James Moe, Ph.D., MBA, President and CEO, Co-Founder, Director, Principal Investigator
Dr. Moe has 20+ years industrial experience having held senior management positions in product development working on international teams in both early and late stage diagnostic, biotechnology and biopharmaceutical companies including Gene-Trak/Amoco Technology Ventures/Vysis, bioMerieux, and Mosaic Technologies. Prior to founding Oligomerix, he was Director of Product Development at Pyrosequencing, Senior Molecular Biologist at Spire Biomedical, and Director of Product Development at Q-RNA, Inc. Dr. Moe received his Ph.D. degree in Molecular Biology/Molecular Biophysics from Wesleyan University, did his postdoctoral studies at Vanderbilt University in the Center for Molecular Toxicology where he was jointly appointed in the Biochemistry Department in the Medical School, and the Chemistry Department in the College of Arts and Sciences, and has an MBA degree with a concentration in entrepreneurial studies from Boston University.
Eliot J. Davidowitz, Ph.D. Chief Scientific Officer, Co-Founder, Director
Dr. Davidowitz has 20+ years of experience in academic and industrial research and development. Prior to founding Oligomerix, he was a Senior Scientist and Laboratory Manager at Q-RNA, Inc. Dr. Davidowitz received his B.S. from Cornell University, Ph.D. from Case Western Reserve University and completed an NIH postdoctoral fellowship at Albert Einstein College of Medicine. His academic work was in molecular and cellular biology and his industrial experience has focused on assay development for drug discovery targeting tau protein for Alzheimer’s disease.
Jack Pasini, MBA, Director, Chief Commercial Officer
Mr. Pasini is the former Pfizer Vice President Worldwide Marketing, Product Development and Business Intelligence and Planning. Prior to joining Oligomerix, Mr. Pasini spent 30 years at Pfizer, Inc. where he held multiple senior level positions and was responsible for some of the company’s most successful brands including Spiriva, Zithromax, Diflucan and Zyvox. Among his career highlights, Mr. Pasini served as Vice President of Pfizer’s Infectious Diseases, Allergy & Respiratory Therapeutic Groups, where he led commercial decision-making involving two key therapeutic areas, generating annual revenue in excess of $5 billion.
Robert Foerster, Chief Financial Officer
Mr. Foerster is a seasoned pharmaceutical executive with experience across numerous financial, therapeutic and functional areas during his 28 years with Pfizer. His roles included Senior Director Commercial Development for Emerging Markets, Senior Director Business Development – Japan, where he was responsible for the entire development portfolio, numerous business alliances, strategic planning, and was a member of the Leadership team. He was Director/Team Leader – Neuroscience for New Product Development, which included the development of Chantix, and Director of Financial Operations for the Africa Middle East region where he was responsible for financial analysis, reporting and compliance. He received his BA in Economics from Dartmouth and MBA Finance from Rutgers.
William Erhardt, M.D., Chief Medical Officer
Dr. Erhardt recently joined Oligomerix as Chief Medical Officer and will be responsible for helping transition Oligomerix’s lead compound through IND and into clinical development. Most recently, he was Senior Vice President, Head of Clinical Development & Operations at Pfizer responsible for design, conduct and reporting of Pfizer’s global Clinical Development portfolio. He oversaw Pfizer’s Clinical, Clinical Sciences, Clinical Project Management and Pfizer’s Internal Phase I Clinical Research units in New Haven and Brussels, Belgium. In this role, Dr. Erhardt was responsible for all Pfizer Clinical Development functions for a portfolio of 350 clinical studies across the Cardiovascular, Metabolic, Neuroscience, Vaccines, Immunology & Inflammation and Rare Disease therapeutic areas and managing a budget of $250M. Dr. Erhardt also spent several years at FDA as Medical Reviewer in the Infectious Diseases group and has excellent understanding of FDA processes. He is a seasoned pharmaceutical executive with broad global experience in medical, clinical operations and development. Dr. Erhardt is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development as well as all aspects of medical product support. His background is complemented by significant organizational design and leadership experience. Dr. Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse. He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children’s National Medical Center.